Frank Li, CEO Stately Bio forecasting biological outcomes
Échec de l'ajout au panier.
Échec de l'ajout à la liste d'envies.
Échec de la suppression de la liste d’envies.
Échec du suivi du balado
Ne plus suivre le balado a échoué
Frank Li, CEO Stately Bio forecasting biological outcomes
-
Narrateur(s):
-
Auteur(s):
À propos de cet audio
(2:10) Frank's background – Stanford, Palantir, Google, Calico, now Stately Bio
(4:35) What Stately Bio does – Marrying brightfield imaging with modern ML for live cell analysis
(8:10) Why brightfield imaging matters – Cheap, live, centuries-old tech meets new machine learning
(12:05) Real-time monitoring and forecasting biological outcomes
(18:20) How living cell observation shrinks iteration cycles
(24:45) Applications to stem cell therapies: diabetes, Parkinson’s, liver, heart, kidney
(30:10) ML advantage – Machine vision finds subtle signals invisible to humans
(35:50) Stately Bio’s early success – New York Blood Center partnership
(40:25) The cost advantage of imaging vs. single-cell omics
(44:30) Platform vs pipeline – Why Stately is building therapies, not just a tool
(50:00) Future verticals: Biomanufacturing, synthetic biology applications
(54:50) Frank’s journey – From coder to founder to biotech CEO
(1:00:05) Challenges in filtering conflicting advice as a founder
(1:04:40) Surprise learnings from scaling Stately
(1:09:00) ISCT conference announcements – New breakthroughs in suspension cells imaging
(1:13:25) Big vision – Starting the phenomics revolution through live-cell analysis